Skip to main content

Table 5 Pharmacokinetic parameters of cabazitaxel on Days 1 and 22 (cycle 1)

From: Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours

  Day 1 Day 22
Dose, mg/m2 Patients treated/with data Cmax, aμg/l AUC0–t, μg.h/l Patients treated/with data Cmax, aμg/l AUC0–t, μg.h/l
1.5 1/1 15.5 17.2 1/1 13.5 28.2
3 1/1 41.9 47.1 1/1 23.0 102
6 4/3 31.2 ± 15.5 (50) 89.7 ± 51.8 (58) 4/3 49.4 ± 13.8 (28) 150 ± 34 (22)
8.4 12/11 71.7 ± 54.4 (76) 144 ± 46 (32) 11/9 70 ± 30.4 (43) 190 ± 89 (47)
10 7/4 102 ± 52 (51) 153 ± 91 (60) 4/4 89.3 ± 80.6 (90) 187 ± 56 (30)
12 6/3 152 ± 148 (97) 212 ± 120 (56) 4/2 84.8–480 145–447
  1. Data are expressed as mean ± SD (CV%).
  2. a Observed value at 5 minutes before the end of infusion except for four patients on Days 1 and for seven patients on Day 22 for whom maximal plasma concentrations were measured 20 minutes before the end of infusion.